Ceritinib (LDK378)

For research use only. Not for use in humans.

目录号：S7083

CAS No. 1032900-25-6

Ceritinib (LDK378)是一种有效的ALK抑制剂，在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。

规格

价格

库存

购买数量

5mg	RMB 1182.86	现货
50mg	RMB 3868.47	现货
200mg	RMB 10720.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ceritinib (LDK378)发表文献76篇：

Cell, 2021, 184(10):2649-2664.e18

PubMed: 33848463 ( click the link to review the publication )

Nature, 2019, 10.1038/s41586-019-1472-0

PubMed: 31391581 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Cell Rep, 2021, 36(7):109515

PubMed: 34407403 ( click the link to review the publication )

Cereb Cortex, 2021, bhab058

PubMed: 33791755 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0221.2021

PubMed: 34158340 ( click the link to review the publication )

ESMO Open, 2021, 6(4):100172

PubMed: 34242968 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9011

PubMed: 33907223 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 39(1):151-163

PubMed: 31462708 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )
Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Biochem J, 2019, 10.1042/BCJ20190106

PubMed: 31341009 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00802-7

PubMed: 31177400 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4162-4174

PubMed: 29776956 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )
Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(6):2487-2499

PubMed: 29742496 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):73-83

PubMed: 29133622 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Cancer Sci, 2017,

PubMed: 27783866 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1118-1125

PubMed: 29045271 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 40(5):1129-1140

PubMed: 27960155 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):601-9

PubMed: 26639656 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1118-1133

PubMed: 27432227 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )
Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Oncol, 2015, 10.1016/j.molonc.2015.11.007

PubMed: 26639656 ( click the link to review the publication )

Oncotarget, 2015, 6(42):44643-59

PubMed: 26556876 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(4):566-571

PubMed: 25450694 ( click the link to review the publication )

产品安全说明书

ALK抑制剂选择性比较

生物活性

产品描述

特性

不与c-Met交叉反应，对体内葡萄糖稳态比TAE684效果好，有效作用于 Crizotinib复发的肿瘤。

靶点

ALK ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	STK22D ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)
0.2 nM	7 nM	8 nM	23 nM	60 nM

体外研究

LDK378作用于Ba/F3-NPM-ALK和Karpas290细胞，具有显著的抗增殖活性，IC50分别为26.0 nM 和 22.8 nM,作用于Ba/F3-Tel-InsR 和Ba/F3-WT细胞，IC50分别为319.5 nM 和 2477 nM。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Parental(+IL3)	NWi1dndbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXK3NkBp	NH\xb3ZFVVOR	M2\pRmlEPTB;MUW4OkDDuSBzN{Ogcm0>	M4DQVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
WT 70	NILodZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUXGbGRiPzJiaB?=	MUjEUXNQ	M3\icWlEPTB;MkGgxtEhQCCwTR?=	MoTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
G1128S 1022	NFrwZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13qcFczKGh?	NYTkWZdDTE2VTx?=	M4CydGlEPTB;MUCyJOKyKDN6IH7N	NIPmV4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
C1156F 1293	M2\xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkHUO\|IhcA>?	NEnrTFlFVVOR	MmTCTWM2OD1{MUegxtEhOTF3IH7N	NIXucYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
I1171N 519	NYHjfodRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGD4coE4OiCq	NF7QbVZFVVOR	MnWwTWM2OD1zOEegxtEhQDdibl2=	M2\ZTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
I1171T 445	NVzvcWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\oRVczKGh?	NES2bFdFVVOR	MVXJR\|UxRTh{INMxJFEzKG6P	MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
F1174I 184	NUjO[nVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2nC[VczKGh?	MVnEUXNQ	M2n1SGlEPTB;MUOgxtEhOC5zIH7N	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
N1178H 169	NITme5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEe4V3A4OiCq	MX7EUXNQ	MXLJR\|UxRTR{INMxJFYhdk1?	NGTsSYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
E1210K 748	NUK3bnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{CxV\|czKGh?	NIf3fZJFVVOR	M{jLUmlEPTB;MUi3JOKyKDh2IH7N	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
C1156F/D1203N 2809	M4izc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYLxTFZHPzJiaB?=	MXfEUXNQ	NWr2S\|ZLUUN3ME2yOVQhyrFiOUmgcm0>	M1u1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
Ba/F3 NA WT	M1v6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4j6eVczKGh?		NYTTT2VtUUN3ME2wMlAzOCEQvF2=	MoLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 NA C1156Y	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\LO\|IhcA>?		M3;jNmlEPTB;MD6wO\|Eh\|ryP	NH\ZSXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 NA L1196M	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoHsO\|IhcA>?		MVrJR\|UxRTBwMESyJO69VQ>?	NWLTbHZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 NA L1152R	M3e3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1TvOVczKGh?		NEPVU4pKSzVyPUCuNlg5KM7:TR?=	NWWwTYNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 NA G1202R	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\zO\|IhcA>?		MmnLTWM2OD1yLkK3O{DPxE1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 NA G1269A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Moi0O\|IhcA>?		MVzJR\|UxRTBwMEG5JO69VQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 NA S1206Y	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4Phc\|czKGh?		NUjtS5VYUUN3ME2wMlA{PyEQvF2=	M1HsblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 EA WT	MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV\FS\|JKPzJiaB?=		MVHJR\|UxRTBwMEKxJO69VQ>?	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA C1156Y	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mli4O\|IhcA>?		M33Uc2lEPTB;MD6wNlYh\|ryP	NGT2PHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 EA L1196M	NVHwRmR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2Ll[\|czKGh?		Mn34TWM2OD1yLkCxPUDPxE1?	M4XFN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 EA L1152R	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUO3NkBp		MnzrTWM2OD1yLkC5PUDPxE1?	NEXJZmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 EA G1202R	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NInKTmg4OiCq		NEDte5NKSzVyPUCuOFY4KM7:TR?=	NUfOO\|V4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 EA G1269A	NY\IOo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFjhVZA4OiCq		M37TNGlEPTB;MD6wN\|Mh\|ryP	MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mke0NFAoRjJ3N{K3OFAxRC:jPh?=
Ba/F3 EA S1206Y	M2HvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYjVPHU4PzJiaB?=		NFz0OplKSzVyPUCuNFM5KM7:TR?=	NVK3eotzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
BAF3	M3TkZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYTRdI1mPzJiaILz		MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMEGwO{DPxE1w	M2jRbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
NCI-H3122	Mn3URY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWmyelM1PzJiaILz		NIntZ2dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDBwMEG1JO69VS5?	NHfLNmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
NCI-H2228	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoLYN{Bl[Xm\|		MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ{MkigZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KGy3bXnu[ZNk\W6lZT3iZZNm\CCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wNVUh\|ryPLh?=	MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4Mke3NlUoRjJ7NkK3O\|I2RC:jPh?=
SU-DHL1	MlT2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVOzJIRigXN?		M2q4R2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNWNUSKTEGgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KGy3bXnu[ZNk\W6lZT3iZZNm\CCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wNVUh\|ryPLh?=	M2jXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK3O\|I2Lz5{OU[yO\|czPTxxYU6=
DFCI114	M{jHTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXq3NkBpenN?		NFrafYdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTGR2kyOTRiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4xOThizszNMi=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
HCC78	M3XUSGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3LUWVczKGi{cx?=		MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEG4JO69VS5?	NHe4OHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OFkzPSd-Mke0O\|Q6OjV:L3G+
KARPAS299	MkDxR5l1d3SxeHnjbZR6KGG\|c3H5		M{LFZVIhfG9iMzDkZZl{		M4eybmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCWlCDU{K5PUBk\WyuczDh[pRmeiB{IITvJFMh\GG7czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCyNlgh\|ryPLh?=	NUTRZVU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
KARPAS299	Ml\IR5l1d3SxeHnjbZR6KGG\|c3H5				MknQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2FTWEGVMkm5JINmdGy\|IHX4dJJme3OrbnegUnBONUGOSzDmeZNqd25iZ3Xu[UBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NEA:KDBwMEKyPEDPxE1w	NYHmNHliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N\|c4QTdpPkKzPFM4Pzl5PD;hQi=>
NCI-H3122	MU\GeY5kfGmxbjDhd5NigQ>?		M1LmUFczKGi{cx?=		MVPJcohq[mm2aX;uJI9nKEWPTESg[pV{\WRiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFPDOVAhRSByLkCyOUDPxE1w	NXK0fmpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVUyPjlpPkK3PVE2OTZ7PD;hQi=>
BAF3	NX\QfmhKTnWwY4Tpc44h[XO\|YYm=		MVKyJJRwKDNiZHH5dy=>		NXq0TWVNUW6qaXLpeIlwdiCxZjDOVG0u\nW\|ZXSgRWxMKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMk[g{txONg>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
BA/F3	MoTPR5l1d3SxeHnjbZR6KGG\|c3H5				MoDaR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCQUF2tRWxMKG[3c3nvckBo\W6nIHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uMEBKSzVyIE2gNE4xOjZizszNMi=>	NHHjeJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izO\|c6Pyd-MkO4N\|c4QTd:L3G+
KARPAS299	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M37meVczKGi{cx?=		NIfSUYFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMk[g{txONg>?	M3W4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUe0PFA6Lz5{OUG3OFgxQTxxYU6=
NCI-H2228	NEnwbpBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlyzO\|IhcHK\|		NYjTZWhySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ{MkigZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyOkDPxE1w	NVyyVVlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
KARPAS299	NUnRc5hmS3m2b4TvfIlkcXS7IHHzd4F6		MYK3NkBpenN?		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMkeg{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR5NEmyOUc,Ojd2N{S5NlU9N2F-
Ba/F3	M1LnXWZ2dmO2aX;uJIF{e2G7		MUe3NkBpenN?		M4rtdWlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiU{GyNFZ[KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC5yM{Og{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
NCI-H3122	NUfhbYdDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NFLlcXdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNuIFPDOVAhRSByLkCzPEDPxE1w	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{W5OFUoRjJ4MkO1PVQ2RC:jPh?=
NCI-H3122	MmfoSpVv[3Srb36gZZN{[Xl?		M1HhbFczKGi{cx?=		NGXPPI9KdmirYnn0bY9vKG:oIFXNUFQuSUyNIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCFQ{WwJF0hOC5yM{ig{txONg>?	NUnacpJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5NlM3QTVpPkK2PVI{Pjl3PD;hQi=>
NCI-H3122	MXLGeY5kfGmxbjDhd5NigQ>?		MUm3NkBpenN?		MXLJcohq[mm2aX;uJI9nKEWPTEStRWxMKGmwIHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBESzVyIE2gNE4xOzhizszNMi=>	MkPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MkO2PVUoRjJ4OUKzOlk2RC:jPh?=
NCI-H3122	NWPpfll1TnWwY4Tpc44h[XO\|YYm=		M3;B[VczKGi{cx?=		MX\Jcohq[mm2aX;uJI9nKEWPTESg[pV{\WRiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFPDOVAhRSByLkCzPEDPxE1w	M1Ky[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{i1OVA2Lz5{OEO4OVUxPTxxYU6=
BA/F3	MXXGeY5kfGmxbjDhd5NigQ>?				NXS0[pdlUW6qaXLpeIlwdiCxZjDBUGshMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczygTWM2OCB;IECuNFQxPyEQvF2u	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh\|N{e5O{c,OjN6M{e3PVc9N2F-
Ba/F3	NF\GOo1HfW6ldHnvckBie3OjeR?=		NX\1cZpYPzJiaILz		M2XDe2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQuSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCwMlA1OSEQvF2u	NUHLXIVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Ba/F3	MXfGeY5kfGmxbjDhd5NigQ>?		MXG3NkBpenN?		NGO1NoZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1NUGOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNE4xPDFizszNMi=>	NGHkblU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
KARPAS299	NEHOc4JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWnUU5c{PzJiaILz		MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPDFizszNMi=>	NFzBT209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKyN\|EzOCd-M{CyNlMyOjB:L3G+
BAF3	NUTGXXVpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1TZO\|czKGi{cx?=		MoTWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDFUWw1NUGOSzDMNVE6Pk1ibYX0ZY51KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODV2OTFOwG0v	NV:1fodGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Ba/F3	M2XuTWZ2dmO2aX;uJIF{e2G7		NEezSGQ4OiCqcoO=		NFHrTllKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFexNlY6SSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEW3JO69VS5?	NYHRNoVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
HCC78	NVzkUFYzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWjFclJCPzJiaILz		NXzLbpNqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC1PEDPxE1w	NYLSNXdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5ODlpPkK5NVc1QDB7PD;hQi=>
HCC78	NFLleYxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXvLRWNOPzJiaILz		MnvnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O3PEBk\WyuczDoZZJjd3KrbnegV2xEOzSDMj3SU3MyKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB3ODFOwG0v	M1zDfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
Ba/F3	NV\uSYd{TnWwY4Tpc44h[XO\|YYm=		NFWwNJU4OiCqcoO=		MU\Jcohq[mm2aX;uJI9nKEWPTEStRWxMKExzMUm2UUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODZ2IN88UU4>	M{\RblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
DFCI76	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M33je\|czKGi{cx?=		M2rHbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF\DTVc3KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshVDFzNULSJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNFczKM7:TT6=	M2DtWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
BAF3	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				Mn\URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHX4dJJme3OrbnegRWxMKExzMUm2UUBufXSjboSsJGNEPTBiPTCwMlA4PSEQvF2u	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ\|NUm0OUc,OjZ{M{W5OFU9N2F-
BA/F3	MXPGeY5kfGmxbjDhd5NigQ>?		M3Ox[\|czKGi{cx?=		M{XxXmlvcGmkaYTpc44hd2ZiQVzLJGwyOTl4TTDteZRidnRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGfTWFEh[XO\|YYmsJGNEPTBiPTCwMlA4PSEQvF2u	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MkO2PVUoRjJ4OUKzOlk2RC:jPh?=
BA/F3	MUDGeY5kfGmxbjDhd5NigQ>?		M3\WTFczKGi{cx?=		NULPdlc{UW6qaXLpeIlwdiCxZjDFUWw1KG[3c3XkJGFNUyCOMUG5Om0hdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44hdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhS0N3MDC9JFAvODd3IN88UU4>	M17nPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG1NVY6Lz5{N{mxOVE3QTxxYU6=
BA/F3	NVHCT45KTnWwY4Tpc44h[XO\|YYm=		M2nVVFczKGi{cx?=		MojUTY5pcWKrdHnvckBw\iCHTVy0JIZ2e2WmIFHMT{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKG2nYYP1doVlKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEOFNUCgQUAxNjB5NTFOwG0v	M4nqe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG1NVY6Lz5{N{mxOVE3QTxxYU6=
BAF3	M3SwUGZ2dmO2aX;uJIF{e2G7		MXi3NkBpenN?		MUDJcohq[mm2aX;uJI9nKEGOSzDMNVE6Pk1ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhX1OWLUGgZZN{[XluIFPDOVAhRSByLkC3OUDPxE1w	NUP6SZFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizPFU2ODVpPkK4N\|g2PTB3PD;hQi=>
KARPAS299	Mn7NRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV7VTI9qPzJiaILz		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlA5PCEQvF2u	NITJfmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SMS-KCNR	NXLIOVhySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX\mRnlDPzJiaILz		NXPpRYF2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQUjDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIGKxNlc2WSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAxNjB7MjFOwG0v	MoDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
NCI-H3122	MkTORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFzQeZY4OiCqcoO=		NYn6R4k1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC5yOU[g{txONg>?	NWrsNWdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
NCI-H2228	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF\YWpc4OiCqcoO=		M4\OZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOUmg{txONg>?	MmHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
Ba/F3	NXTyfHB3TnWwY4Tpc44h[XO\|YYm=		Ml3xO\|IhcHK\|		MX7Jcohq[mm2aX;uJI9nKEWPTEStRWxMKEZzMUe0UEBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvOTBzIN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
NCI-H2228	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		MnrnO\|IhcHK\|		MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ{MkigZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUCyOkDPxE1w	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ2NE[3NUc,OjV4NES2O\|E9N2F-
LAN5	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{TTUFczKGi{cx?=		MlPWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOQV61JINmdGy\|IHX4dJJme3OrbnegSW1NPC2DTFugVlEzPzWTIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDBwMUKyJO69VS5?	MlTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
SU-DHL1	NHO5d5pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH:4eJc4OiCqcoO=		NX;GUWkySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWU1FUExzIHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOTJ{IN88UU4>	NUDLNINIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Kelly	NXPoWIZ[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NV\EPGF1PzJiaILz		NWrIUVh4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlE1OiEQvF2u	MnnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Ba/F3	MnHrSpVv[3Srb36gZZN{[Xl?		NGrLToU4OiCqcoO=		MVTJcohq[mm2aX;uJI9nKEWPTEStRWxMKENzMUW2XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvOTZ2IN88UU4>	M4q1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
SH-SY5Y	MkLBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1PuW\|czKGi{cx?=		M1nUWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1itV3k2YSClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlE5PiEQvF2u	M134UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
BAF3	NInJPYZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVW3SFltPzJiaILz		MoHJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDDSFc1NVKRU{GgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBweiCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6yN\|Qh\|ryPLh?=	M1zrb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
SK-N-SH	M{\KRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkL1O\|IhcHK\|		NXraNHZwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNVOKIHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtiRkGxO\|RNKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhTUN3MDC9JFAvOzB\|IN88UU4>	M4fiNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
BAF3	MmTuSpVv[3Srb36gZZN{[Xl?		NGDJdJQzKHSxIEOg[IF6ew>?		NYrXTJJ[UW6qaXLpeIlwdiCxZjDUSWwu\nW\|ZXSgbY5{fWyrbjDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEKgeI8hOyCmYYnzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuN\|E6PSEQvF2u	NVLEdo56RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BA/F3	MnK3R5l1d3SxeHnjbZR6KGG\|c3H5				MojkR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMhfHKjboPm[YN1\WRid3n0bEBV\WxvSX7zVkBo\W6nIHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uMEBKSzVyIE2gNE4{OiEQvF2u	NWXVblBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N\|c4QTdpPkKzPFM4Pzl5PD;hQi=>
SK-N-FI	M3HYcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXm3NkBpenN?		MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tSmkh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhTU2OND3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAxNjN2OTFOwG0v	NYPRboJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
CHLA20	MkPPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXK3NkBpenN?		NYHuTYhTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDTGxCOjBiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCUMUK3OXEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4{PjNizszNMi=>	NFHCXJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Ba/F3	MXjGeY5kfGmxbjDhd5NigQ>?		NHHNdoM4OiCqcoO=		NULKNYU1UW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDHNVIxOlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkS0OEDPxE1w	MoDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
LAN1	NWHLNnFHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnfSO\|IhcHK\|		NWfIXFdESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMRW4yKGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuOVQ6KM7:TT6=	M{HYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
SK-N-BE(2)	M1\C[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M175UlczKGi{cx?=		MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tRmUpOiliY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkW5N{DPxE1w	MlTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Ba/F3	MkDnSpVv[3Srb36gZZN{[Xl?		NWnlO3g4PzJiaILz		NIPGeJNKdmirYnn0bY9vKG:oIFXNUFQuSUyNIEGxOVFVcW6\|IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD62Olgh\|ryPLh?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
BAF3	MniyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYnvfI4yPzJiaILz		MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIFexNlAzWiCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE44OjZizszNMi=>	MmnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Ba/F3	NEfQWmlHfW6ldHnvckBie3OjeR?=		MmXIO\|IhcHK\|		NYLIcpFuUW6qaXLpeIlwdiCxZjDoeY1idiCHR1\SJIRmdDF7L2S3PVBON0N5OUfTJI12fGGwdDDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvPzhyNTFOwG0v	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF\|NkS2OUc,OjlzM{[0OlU9N2F-
SK-N-AS	NWfxbWwzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUW3NkBpenN?		NG\tR41CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uSVNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSBzLkC0OUDPxE1w	NIPLUm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	NXTaT41zS3m2b4TvfIlkcXS7IHHzd4F6		NHT2eY0zKHSxIEOg[IF6ew>?		M3LmV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgNkB1dyB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNk41PzdizszNMi=>	M17XZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SyNlUzLz5{M{e0NlI2OjxxYU6=
Ba/F3	M4LFXWZ2dmO2aX;uJIF{e2G7		M33rbVczKGi{cx?=		M{fYU2lvcGmkaYTpc44hd2ZiRV3MOE1CVEtiTEGxOVJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOi55NEeg{txONg>?	M336fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
BA/F3	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		M2fYWlczKGi{cx?=		Mof1R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFUvPTF{IN88UU4>	NHn3ZlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
KARPAS299	NWW4XGIySXCxcITvd4l{KGG\|c3H5	M4S5WFYxKG6P	MYKyOEBpenN?		NIfGbIFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjdDC2NEBvVSCjZoTldkAzPCCqcoOgZpkh[WO{aXTpcoUhd3KjbnflM4V1cGmmaYXtJIJzd22rZHWgd5RicW6rbnegZoF{\WRiZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKG2ndHjv[C=>	NW\BUZdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5ODlpPkK5NVc1QDB7PD;hQi=>
SU-DHL1	NEfv[WdHfW6ldHnvckBie3OjeR?=	MVmyNEB1dyB{MECgcm0>	NH6xNm0yKGi{		MlmyTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JHk4ODVicnXzbYR2\SCjdDCyNEB1dyB{MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MmXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
SU-DHL1	NX7DcZE4TnWwY4Tpc44h[XO\|YYm=	M2jYcVIxKHSxIEKwNEBvVQ>?	MmnzNUBpeg>?		MWHJcohq[mm2aX;uJI9nKEGOSzDwbI9{eGixconsZZRqd25iYYSgXVEzPzhicnXzbYR2\SCrbjDoeY1idiCVVT3ETGwyKGOnbHzzJIF1KDJyIITvJFIxOCCwTTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MlzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122	MlL0SpVv[3Srb36gZZN{[Xl?	NX\2XZF1OjBidH:gNlAxKG6P	Mn73NUBpeg>?		Ml2yTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODJxL2myNFQhemW\|aXT1[ZMh[XRiMkCgeI8hOjByIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M1LwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
NCI-H3122	M2C2TWZ2dmO2aX;uJIF{e2G7	NXXh[lJoOjBidH:gNlAxKG6P	M4XsN\|EhcHJ?		NUXTNGh[UW6qaXLpeIlwdiCxZjDBUGshcW5iaIXtZY4hVkOLLVizNVIzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFN2N{OgdoV{cWS3ZTDheEAzOCC2bzCyNFAhdk1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NVSwbZdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
SU-DHL1	NXznW4ZvTnWwY4Tpc44h[XO\|YYm=	MnjaNlAhfG9iMkCwJI5O	Mnn2NUBpeg>?		MVjJcohq[mm2aX;uJI9nKEGOSzDpckBpfW2jbjDTWU1FUExzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCc3RicHjvd5Bpd3K7bHH0bY9vKGG2IGO0O\|MhemW\|aXT1[UBifCB{MDD0c{AzODBibl2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M1XUfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
SU-DHL1	MnfhSpVv[3Srb36gZZN{[Xl?	NGHUOHQzOCC2bzCyNFAhdk1?	Mn3xNUBpeg>?		MUTJcohq[mm2aX;uJI9nKEGOSzDpckBpfW2jbjDTWU1FUExzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9vKGG2IGSyNFIwN1l{MESgdoV{cWS3ZYOgZZQhOjBidH:gNlAxKG6PIHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
NCI-H3122	NHKwXXhHfW6ldHnvckBie3OjeR?=	MkSwNlAhfG9iMkCwJI5O	NW\JeZI2OSCqch?=		NUXTU4d6UW6qaXLpeIlwdiCxZjDBUGsheGixc4Doc5J6dGG2aX;uJIF1KFlzMke4JJJme2mmdXWgbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHH0JFIxKHSxIEKwNEBvVSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NUfqS5ByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
NCI-H3122	MUjGeY5kfGmxbjDhd5NigQ>?	NGPtNnozOCC2bzCyNFAhdk1?	MWixJIhz		NXy4VopJUW6qaXLpeIlwdiCxZjDBUGshcW5iaIXtZY4hVkOLLVizNVIzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBz\XOrZIXlJIF1KDJyIITvJFIxOCCwTTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M{fOXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
SU-DHL1	NH;6W4JHfW6ldHnvckBie3OjeR?=	MUSzNEBvVQ>?	NW\3OoNkOTZiaILz		NGG1WGZKdmirYnn0bY9vKG:oIFHMT{BifXSxcHjvd5Bpd3K7bHH0bY9vKGG2IGmxOVA4KHKnc3nkeYUhcW5iaIXtZY4hW1VvRFjMNUBk\WyuczDheEA{OCCwTTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NI\iXZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[yO\|czPSd-Mkm2Nlc4OjV:L3G+
SU-DHL1	MkPWSpVv[3Srb36gZZN{[Xl?	NVnW[XpkOzBibl2=	MnnSNVYhcHK\|		MkXsTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JHk4ODVicnXzbYR2\SCjdDCzNEBvVSCjZoTldkAyPiCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NGD4dms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[yO\|czPSd-Mkm2Nlc4OjV:L3G+
NCI-H3122	NX\QR\|FGTnWwY4Tpc44h[XO\|YYm=	NGHy[\|A2OCC2bzCyOVAhdk1?	NYiyXHo6OTZiaILz		NGDQNoVKdmS3Y4Tpc44hd2ZiQVzLJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDBUGsheGixc4Doc5J6dGG2aX;uJIF1KFlzNkC0JIF1KDVyIITvJFI2OCCwTTDh[pRmeiBzNjDodpMh[nliaX3teY5w[myxdDDt[ZRpd2R?	M3;USFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
SH-SY5Y	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2\sVlczKGi{cx?=		NXnsdVg2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ4MEm4OEc,Ojl4NkC5PFQ9N2F-
CHLA20	NX7JNoVvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGTISXM4OiCqcoO=		NYn2eIE4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDTGxCOjBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZk>	M1fQT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
SH-SY5Y	M3rWZ2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M33IN\|czKGi{cx?=		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOKLWPZOXkh[2WubIOgZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJGFDS0JzIHnubIljcXSxcjD0ZZJqeXWrZHHyJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[Xl?	NXL6c202RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OlA6QDRpPkK5OlYxQTh2PD;hQi=>
KARPAS299	MY\GeY5kfGmxbjDhd5NigQ>?	NXHXXmcxPTBidH:gNlUxKG6P	NVvTNHZIOTZiaILz		NWfmemc{UW6mdXP0bY9vKG:oIFHMT{Bl\We{YXTheIlwdiCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gRWxMKHCqb4PwbI9zgWyjdHnvckBifCC\MU[wOEBifCB3MDD0c{AzPTBibl2gZYZ1\XJiMU[gbJJ{KGK7IHntcZVvd2Kub4SgcYV1cG:m	MkDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
CHLA20	M1[zRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEjWOmk4OiCqcoO=		NIDjNoxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUGEzOCClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhSUKFQkGgbY5pcWKrdH;yJJRiemmzdXnkZZIh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ4MEm4OEc,Ojl4NkC5PFQ9N2F-
NCI-H3122	MorHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVy3NkBpenN?		M{XlfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ4MEm4OEc,Ojl4NkC5PFQ9N2F-
KARPAS299	M1r0VWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGLXU5o4OiCqcoO=		Mk\kRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZk>	NIPWNGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
SU-DHL1	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIK1WoY4OiCqcoO=		M4e0[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfS=>	M3XFS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
KARPAS299	NF7DVHZCeG:ydH;zbZMh[XO\|YYm=	NIfMZpU2OCCwTR?=	MVyyOEBpenN?		MW\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bie3Onc4Pl[EBieyC3bnPs[YFzKGOnbHygd4hzcW6tYXflJIF1KDVyIH7NJIFnfGW{IEK0JIhzeyCkeTDIc4VkcHO2IEOzNlU5KHO2YXnubY5oKGKjc3XkJIlvfmW{dHXkJIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7	NXmwflhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
KARPAS299	MlHmRZBweHSxc3nzJIF{e2G7	NX7Mc2htPTBibl2=	MVWyOEBpenN?		NYr3doh3UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgcIF1\SCjcH;weI91cWNiY3XscJMh[XRiNUCgcm0h[W[2ZYKgNlQhcHK\|IHL5JGFQN0WEIHTveYJt\SC\|dHHpcolv\yCkYYPl[EBqdn[ncoTl[EBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yeR?=	Ml7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
KARPAS299	MVrBdI9xfG:\|aYOgZZN{[Xl?	MmO4OVAhdk1?	Ml\WNlQhcHK\|		NEPs[FNKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCjc4Pld5Nm\CCjczDmdoFodWWwdHH0bY9vKGG2IEWwJI5OKGGodHXyJFI1KGi{czDifUBJd2WlaIP0JFM{OjV6IIP0ZYlvcW6pIHLhd4VlKGmwdnXyeIVlKG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5	M{fhV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK; PubMed: 28425916 eLife Inhibition of ALK autophosphorylation and downstream signaling by ceritinib, crizotinib and PF06463922 in NB-1 cells. Cells were harvested after treatment for 4 hr with the indicated compounds at different concentrations. Whole cell lysates were analyzed by Western blotting to detect the levels of ALK, AKT and ERK proteins and their phosphorylation. pROS1 / ROS1 / pSTAT3 / STAT3 ; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.	28425916 25351743
Growth inhibition assay	Cell viability; PubMed: 29067644 Target Oncol The effects of ceritinib treatment on cell viability in ARMS and ERMS cell lines. Cells were treated with 0-5 μM ceritinib for 72 h (Rh30, RD), 120 h (Rh41), or 144 h (Rh18, Aska) and cell viability was assessed. The y-axis represents relative cell viability compared to non-treated cells (control). Effects on cell viability were determined in triplicate. Values are presented as mean ± SD. Dotted line represents the IC50-value. The human synovial sarcoma cell line Aska with constitutive ALK phosphorylation was used as a positive control.	29067644

体内研究

LDK378 用于降低形成反应代谢的可能性，在肝微粒体几乎检测不到谷胱甘肽（GSH）加合物的水平（<1％）。LDK378具有相对良好的代谢稳定性，中度抑制CYP3A4（Midazolam底物）和抑制hERG。LDK378处理动物，与肝脏血流量相比，具有低的血浆清除率（小鼠，大鼠，狗和猴），处理小鼠，大鼠，狗和猴的口服生物利用度都在55％以上。LDK378 处理Karpas299 和H2228 大鼠移植瘤模型，抑制肿瘤生长，诱导肿瘤衰退，这种作用具有剂量依赖性，体重没有降低。LDK378处理小鼠，剂量高达100 mg/kg，对胰岛素水平或血浆葡萄糖的利用无影响。^[1]

激酶实验：^[1]	- 合并激酶分析: 所有激酶使用杆状病毒表达技术表达为组氨酸或GST标签的融合蛋白，除了在大肠杆菌中产生的未标记的ERK2。在LabChip迁移实验中测量激酶活性。实验在30°C下进行60分钟。在有或无LDK378存在时，通过线性进展曲线，获得LDK378对酶活性的作用效果。
细胞实验：^[1]	- 合并 Cell lines: Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 细胞 Concentrations: ~100 μM Incubation Time: 2-3 天 Method: 表达荧光素酶的细胞与连续稀释的LDK378 或 DMSO 温育2-3天。荧光素酶的表达用来衡量细胞增殖/存活，使用Bright-Glo萤光素酶检测系统来评估。使用 XLFit软件获得 IC50值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带 Karpas299/H2228肿瘤的 RNU裸鼠 Dosages: ~50 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

溶解度 (25°C)

体外	DMSO	20 mg/mL warmed (35.83 mM)
	Ethanol	3 mg/mL (5.37 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ceritinib (LDK378) SDF

分子量	558.14
化学式	C₂₈H₃₆ClN₅O₃S
CAS号	1032900-25-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02450903	Completed	Drug: LDK378	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	August 21 2015	Phase 2
NCT02040870	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	March 7 2014	Phase 1\|Phase 2
NCT01950481	Completed	Drug: LDK378	Normal Hepatic Function\|Impaired Hepatic Function	Novartis Pharmaceuticals\|Novartis	January 2014	Phase 1
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01685060	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	November 26 2012	Phase 2
NCT01634763	Completed	Drug: LDK378	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Novartis Pharmaceuticals\|Novartis	June 2012	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to reconstitute the inhibitor for oral administration to mice?
回答：
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

非特异性的ALK抑制剂

GSK1838705A : IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.
FDA批准的ALK抑制剂

Crizotinib (PF-02341066) : Approved by FDA for non-small cell lung carcinoma (NSCLC).
最新的ALK抑制剂

ASP3026 ^New : Novel and selective inhibitor for ALK with IC50 of 3.5 nM.
经典的ALK抑制剂

TAE684 (NVP-TAE684) : Potent and selective ALK inhibitor with IC50 of 3 nM, 100-fold more sensitive for ALK than InsR.

研究领域

产品类型

定制您的化合物库

Ceritinib (LDK378)

客户使用Selleck生产的Ceritinib (LDK378)发表文献76篇：

产品安全说明书

ALK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ceritinib (LDK378) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

相关ALK产品